唐力表示，下一步，天津金融系统将充分利用好适度宽松的货币政策，综合运用多种金融工具，加大面 向京津冀协同发展各领域资金供给。强化协同机制，深化三地新一轮金融合作协议落实，形成共建共 享"一盘棋"。 持续推动租赁和保理行业创新发展 天津市作为国家租赁创新示范区和全国商业保理之都，融资租赁、商业保理等特色金融业态经历了从无 到有、从有到强的过程，未来，天津市在推动特色金融创新发展方面有哪些举措？ 天津市地方金融管理局一级巡视员黎红表示，目前，天津市率先探索推出保税租赁、离岸租赁、绿色租 赁等数十种新的业务模式，开展了司法、外汇、海关等多方面创新试点，出台国内首个绿色租赁和绿色 保理团体标准，填补了国内空白。截至2024年末，融资租赁（含金融租赁）资产规模超2.3万亿元，船 舶海工等跨境租赁业务全国占比90％以上，商业保理资产规模超3000亿元，保理融资款余额超2500亿 元，保持全国领先优势。租赁公司服务中小微企业资产余额5760亿元，同比增长15％，全市绿色租赁资 产余额5574亿元，同比增长16％。 下一步，天津市将持续推动租赁和保理行业创新发展。在融资租赁方面，重点打造飞机租赁、船舶租 赁、出口租赁离岸贸易 ...

Summary of Tarsus Pharmaceuticals (TARS) 2025 Conference Call Company Overview - Tarsus Pharmaceuticals is a commercial company based in Orange County, California, focusing on eye care treatments, particularly the launch of their drug Xtampi for blepharitis treatment [3][4]. Key Highlights - **Product Launch Success**: The launch of Xtampi has exceeded expectations, with Q1 revenue recorded at approximately $78.2 million, representing a 20% growth from Q4 [4]. - **Market Potential**: The drug targets a significant patient population, with an estimated 25 million patients in the U.S. suffering from demodex-related conditions, and aims to reach 9 million patients actively visiting doctors [3][4]. - **Sales Force Impact**: The expansion of the sales force has been a major tailwind, contributing to extraordinary growth in Q1, surpassing initial expectations despite typical seasonal challenges [19][20]. Financial Metrics - **Revenue and Dispensed Bottles**: In Q1, Tarsus dispensed 72,000 bottles of Xtampi, with a gross-to-net discount of about 47%, expected to decline to the low 40s in subsequent quarters [4]. - **Patient Coverage**: Over 90% of lives are covered by payers for Xtampi, which is considered remarkable in the current environment [11][12]. Pipeline Developments - **Ocular Rosacea**: Tarsus is initiating a Phase II study for ocular rosacea, targeting 15-18 million patients, with no current FDA-approved treatments available [5][58]. - **Lyme Disease Program**: A prophylactic oral treatment for Lyme disease is also in the pipeline, with plans for a Phase 2b study in 2026 [6]. Competitive Landscape - **Lack of Competition**: Xtampi is positioned as a best-in-class product with no direct competition, as existing treatments do not effectively address the root cause of demodex infestation [10][16]. - **Potential Complementary Products**: Other products in development, such as pimecrilimus, may serve as complementary treatments rather than direct competitors [14][15]. Market Dynamics - **Optometrist Engagement**: The trend of optometrists taking on more medical management roles is increasing, allowing them to bill for comprehensive exams and follow-ups, which enhances patient retention and practice growth [34][37]. - **Direct-to-Consumer (DTC) Marketing**: The DTC program is showing promising early results, with increased website visits and engagement correlating with future prescription growth [29][30]. Future Outlook - **TAM Growth**: The total addressable market (TAM) is expected to grow, with the potential to treat a significant portion of the 9 million targeted patients over time [45][46]. - **Data Generation**: Tarsus plans to conduct multiple Phase IV studies to expand its market presence and validate the efficacy of its products across various patient segments [48]. Regulatory and Market Considerations - **Medicare Part D Impact**: The introduction of Medicare Part D coverage has reduced friction for patient access, positively impacting revenue [50][52]. - **Exploration of International Markets**: Tarsus is considering opportunities in Europe but currently focuses on the U.S. market [56]. Conclusion - Tarsus Pharmaceuticals is positioned for significant growth with its innovative product offerings and strategic market engagement, particularly in the eye care sector. The company is optimistic about its future prospects, driven by a strong sales force, effective marketing strategies, and a robust pipeline of new treatments.

Service Corporation International (SCI) 2025 Conference May 13, 2025 05:20 PM ET Speaker0 Thanks so much for joining the BofA Healthcare Conference. My name is Joanna Gajuk. I'm the healthcare facilities and managed care analyst here. And it's my pleasure now to host this session with Service Corp, which is the largest operator of funeral homes So it's not necessarily healthcare, but I guess it fits well with my coverage universe. And today with us is Eric Thunsberger, who's the CFO. And I guess the plan is ...

Core Insights - Robinhood Markets, Inc. reported select monthly operating data for April 2025, highlighting growth in funded customers and total platform assets [1][3]. Customer Metrics - Funded customers reached 25.9 million in April 2025, an increase of approximately 120 thousand from March 2025 and up about 2 million year-over-year, reflecting an 8% annual growth [2][3]. Asset Growth - Total platform assets amounted to $232.3 billion at the end of April 2025, representing a 5% increase from March 2025 and an 88% increase year-over-year [2][3]. Deposits - Net deposits for April 2025 were $6.8 billion, showing a 37% annualized growth rate compared to March 2025. Over the last twelve months, net deposits totaled $59.2 billion, with an annual growth rate of 48% relative to April 2024 [3]. Trading Volumes - Equity notional trading volumes were $157.8 billion in April 2025, up 26% from March 2025 and up 123% year-over-year. Options contracts traded were 167.5 million, roughly flat compared to March 2025 but up 32% year-over-year [2][3]. Crypto Trading - Crypto notional trading volumes decreased to $8.6 billion, down 24% from March 2025 and down 15% year-over-year [2][3]. Margin and Cash Sweep - Margin balances at the end of April were $8.4 billion, down 5% from March 2025 but up 105% year-over-year. Total cash sweep balances were $28.9 billion, up 2% from March 2025 and up 51% year-over-year [3]. Securities Lending Revenue - Total securities lending revenue for April was $25 million, reflecting a 4% increase from March 2025 and a 19% increase year-over-year [2][3].

电子行业周报：人工智能自立自强，是年轻的事业也是年轻人的事业 [Table_IndRank] 行业评级：增持 报告日期：2025-05-05 [Table_Chart] 行业指数与沪深 300 走势比较 -20% -10% 0% 10% 20% 30% 40% 50% 5/24 8/24 11/24 2/25 电子(申万) 沪深300 [Table_Author] 分析师：陈耀波 执业证书号：S0010523060001 邮箱：chenyaobo@hazq.com [Table_Author] 分析师：李美贤 [Table_IndNameRptType] 电子 行业周报 执业证书号：S0010524020002 邮箱：limeixian@hazq.com [Table_Author] 分析师：刘志来 执业证书号：S0010523120005 邮箱：liuzhilai@hazq.com [Table_Author] 分析师：李元晨 执业证书号：S0010524070001 邮箱：liyc@hazq.com 相关报告 主要观点： ⚫[Table_Summary] 本周行情回顾 从指数表现来看，本周（2025-04 ...

Broadridge Financial Solutions (BR) Q3 2025 Earnings Call May 01, 2025 08:30 AM ET Company Participants Edings Thibault - Head, Investor RelationsTim Gokey - Chief Executive OfficerAshima Ghei - Chief Finalcial OfficerDaniel Perlin - Managing DirectorScott Wurtzel - SVP - Equity ResearchMichael Infante - Vice President - Equity ResearchPuneet Jain - Associate - Equity ResearchPatrick O'Shaughnessy - Managing DirectorPeter Heckmann - MD - Equity Research Operator Please note this event is being recorded. I w ...

Broadridge Financial Solutions (BR) Q3 2025 Earnings Call May 01, 2025 08:30 AM ET Speaker0 Please note this event is being recorded. I would now like to turn the conference over to Eddings Tivo, Head of Investor Relations. Please go ahead. Speaker1 Thank you, Dave, and good morning, everybody, and welcome to Broadridge's third quarter and fiscal year twenty twenty five earnings call. The earnings release and the slides that accompany this call may be found on the Investor Relations section of broadridge.co ...

Investment Rating - The report does not explicitly state an investment rating for the industry [2]. Core Insights - The report highlights that China achieved a growth target of "around 5%" in 2024, with 70% of this growth driven by exports and export-related manufacturing investment [7]. - For 2025, the report anticipates a decline in real GDP growth to 4.0%, influenced by elevated US tariffs on Chinese goods, which are expected to impose a 2.2 percentage point drag on GDP growth [10][20]. - The report expresses caution regarding medium- to long-term GDP growth in China due to challenges related to demographics, debt, and de-risking, although there are moderate upside risks from faster AI adoption [9]. Summary by Sections Economic Forecasts - The report provides a detailed forecast for China's GDP growth, projecting 5.0% for 2024 and 4.0% for 2025, with a further decline to 3.5% in 2026 [15]. - It notes that domestic demand is expected to contribute positively, with consumption growth projected at 5.3% in 2025 [11]. Tariff Impact - The report indicates that the effective US tariff rate on China has reached 107%, significantly affecting trade dynamics and economic growth [20]. - It emphasizes that the ongoing policy easing in China may not fully offset the negative impacts of these tariffs [12]. Policy Measures - The report outlines expected policy measures, including further monetary easing and fiscal stimulus, to support economic growth amid external pressures [31]. - It anticipates an increase in the augmented fiscal deficit to 14.5% of GDP in 2025, up from 10.4% in 2024 [33]. Sectoral Insights - The report discusses the property sector, noting that construction activity has sharply contracted compared to previous peaks, raising questions about the sustainability of any recovery [52][56]. - It also highlights that high-tech manufacturing has been a stable growth driver over the past decade, with expectations that these sectors will continue to outperform broader manufacturing [80][84].

Core Viewpoint - Beneficient is urging stockholders to vote on proxy proposals ahead of the Annual Meeting scheduled for April 30, 2025, emphasizing the importance of participation to meet quorum requirements [1][4]. Company Overview - Beneficient (NASDAQ: BENF) is a technology-enabled platform that provides exit opportunities, primary capital solutions, and related trust and custody services for holders of alternative assets through its online platform, AltAccess [1][5]. - The company aims to democratize the global alternative asset investment market, targeting mid-to-high net worth individuals, small-to-midsized institutions, and General Partners seeking exit options and value-added services [5]. Voting Information - Stockholders are encouraged to vote by April 29, 2025, through various methods including online, telephone, or by mailing a proxy card [2]. - The Annual Meeting will be held virtually, and stockholders who have already voted do not need to take further action unless they wish to change their vote [3][2]. Regulatory Compliance - Beneficient Fiduciary Financial, L.L.C., a subsidiary of the company, has received its charter under the State of Kansas' Technology-Enabled Fiduciary Financial Institution (TEFFI) Act and is subject to regulatory oversight [6]. Proxy Statement Information - The company has filed a definitive proxy statement with the U.S. Securities and Exchange Commission (SEC) regarding the solicitation of proxies for the Annual Meeting [7]. - Stockholders are encouraged to read all relevant documents filed with the SEC before making any voting decisions, as they contain important information [7].

Company Overview - Beneficient (NASDAQ: BENF) is a technology-enabled platform that provides exit opportunities and primary capital solutions, along with trust and custody services for holders of alternative assets through its online platform, AltAccess [1][6] - The company aims to democratize the global alternative asset investment market, targeting mid-to-high net worth individuals, small-to-midsized institutions, and General Partners seeking exit options and value-added services [6] Annual Meeting Details - The Annual Meeting of Stockholders was adjourned due to insufficient shares present to constitute a quorum, allowing more time for stockholders to vote [2] - The meeting is rescheduled to reconvene on April 16, 2025, at 9:00 a.m. Central time, and will be held virtually [3] - During the adjournment, the company will continue to solicit proxies from stockholders regarding the proposals in the proxy statement [4] Voting Information - Stockholders are encouraged to vote before April 15, 2025, at 11:59 p.m. Central time, with options to vote via internet, telephone, or by returning a proxy card [5] - Proxies previously submitted will be voted at the reconvened meeting unless revoked, and stockholders who have already voted need not take further action unless they wish to change their vote [4] Regulatory Information - Beneficient Fiduciary Financial, L.L.C., a subsidiary of the company, received its charter under the State of Kansas' Technology-Enabled Fiduciary Financial Institution (TEFFI) Act and is subject to regulatory oversight [7] Proxy Statement - The company has filed a definitive proxy statement with the U.S. Securities and Exchange Commission (SEC) for the Annual Meeting, which includes important information for stockholders [8]